AbbVie
ABBV
$160.34
Share price
-0.59%
Change (1 day)
9.38%
Change (1 year)
Categories
The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol “ABBV”.
AbbVie (ABBV) - P/B ratio
P/B ratio as of May 2024 : 27.4
According to AbbVie's latest financial reports the company has a price-to-book ratio of 27.4.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
AbbVie - P/B ratio (from 2012 to 2023)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2023-12-31 | 26.3 | 59.17% |
| 2022-12-31 | 16.5 | 6.61% |
| 2021-12-31 | 15.5 | 7.36% |
| 2020-12-31 | 14.4 | -190.14% |
| 2019-12-31 | -16.0 | -0.73% |
| 2018-12-31 | -16.1 | -153.29% |
| 2017-12-31 | 30.3 | 37.99% |
| 2016-12-31 | 22.0 | -9.2% |
| 2015-12-31 | 24.2 | -59.56% |
| 2014-12-31 | 59.8 | 220.35% |
| 2013-12-31 | 18.7 | 16.28% |
| 2012-12-31 | 16.0 | |
| 2011-12-31 | N/A |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 1.80 | -93.41% | 🇺🇸 USA |
 Eli Lilly LLY | 55.8 | 103.83% | 🇺🇸 USA |
 Amgen AMGN | 26.6 | -3.07% | 🇺🇸 USA |
 Biogen BIIB | 2.16 | -92.13% | 🇺🇸 USA |
 Gilead Sciences GILD | 3.70 | -86.50% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 5.52 | -79.85% | 🇺🇸 USA |
 AstraZeneca AZN | 6.40 | -76.63% | 🇬🇧 UK |
 GlaxoSmithKline GSK | 5.53 | -79.82% | 🇬🇧 UK |
 Neurocrine Biosciences
NBIX | 5.74 | -79.04% | 🇺🇸 USA |